Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Enterprise Value: 2019-2024

Historic Enterprise Value for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to -$147.3 million.

  • Silence Therapeutics' Enterprise Value fell 52.01% to -$122.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.4 million, marking a year-over-year decrease of 52.01%. This contributed to the annual value of -$147.3 million for FY2024, which is 39.31% down from last year.
  • Per Silence Therapeutics' latest filing, its Enterprise Value stood at -$147.3 million for FY2024, which was down 39.31% from -$105.8 million recorded in FY2023.
  • Silence Therapeutics' 5-year Enterprise Value high stood at -$37.2 million for FY2020, and its period low was -$147.3 million during FY2024.
  • For the 3-year period, Silence Therapeutics' Enterprise Value averaged around -$107.0 million, with its median value being -$105.8 million (2023).
  • Per our database at Business Quant, Silence Therapeutics' Enterprise Value plummeted by 172.24% in 2021 and then soared by 32.95% in 2022.
  • Silence Therapeutics' Enterprise Value (MRY) stood at -$37.2 million in 2020, then tumbled by 172.24% to -$101.2 million in 2021, then skyrocketed by 32.95% to -$67.8 million in 2022, then crashed by 55.89% to -$105.8 million in 2023, then tumbled by 39.31% to -$147.3 million in 2024.
  • Its last three reported values are -$147.3 million in FY2024, -$105.8 million for FY2023, and -$67.8 million during FY2022.